文献速递血液净化与透析肾血管病与高血压

DOPPS数据提示血液透析患者使用RAASi及其他降压药可能带来生存获益

DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.
PubMed 文献 · Kidney Int · 2018-06-13

基于DOPPS 2-5期(2002-2015)数据,纳入11,421例新发和37,124例 prevalent 血液透析患者,采用Cox回归分析入组时RAASi及其他降压药处方与死亡率的关联。结果显示RAASi处方与新发患者死亡风险降低相关(aHR 0.89,95%CI 0.80-0.99),prevalent 患者为0.94(0.90-0.99),β受体阻滞剂和钙通道阻滞剂也呈负相关。

要点

  • RAASi在新发血透患者中aHR 0.89,prevalent 患者aHR 0.94,均与较低死亡风险相关。
  • β受体阻滞剂和钙通道阻滞剂也与死亡率呈负相关,ARB关联强于ACEI但需进一步研究。
  • RAASi处方率39%,在合并CHF或CAD患者中差异不大。

核心结论

  • RAASi及其他降压药在血液透析患者中可能带来相对较小的生存获益,但需随机前瞻性研究验证以改变处方标准。

研究设计与样本

  • 国际DOPPS 2-5期(2002-2015)数据,纳入11,421例新发(≤120天)和37,124例prevalent(>120天)血液透析患者,采用Cox回归分析入组时降压药处方与死亡率的关联。

主要发现

  • RAASi处方率39%,在合并CHF和CAD患者中变化很小;超过95%的RAASi为ACEI或ARB。
  • RAASi(vs 无RAASi)调整后风险比:新发患者0.89(95%CI 0.80-0.99),prevalent 患者0.94(95%CI 0.90-0.99)。
  • 未发现与糖尿病、CAD或CHF的交互作用有令人信服的证据;β受体阻滞剂和钙通道阻滞剂也与死亡率呈负相关,ARB关联强于ACEI但需进一步研究。

临床怎么用

  • 在血液透析患者中处方RAASi或其他降压药时,可考虑其可能的生存获益,但需权衡高钾血症等风险。
  • 当前证据不足以改变处方标准,临床决策应个体化并等待随机前瞻性研究结果。

局限性

  • 观察性设计不能确定因果关系,可能存在残余混杂。
  • 原文指出需要随机前瞻性研究来潜在改变处方标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The benefits of renin angiotensin-aldosterone system inhibitors (RAASi) are well-established in the general population, particularly among those with diabetes, congestive heart failure (CHF), or coronary artery disease (CAD). However, conflicting evidence from trials and concerns about hyperkalemia limit RAASi use in hemodialysis patients, relative to other antihypertensive agents, including beta blockers and calcium channel blockers. Therefore, we investigated prescription patterns and associations with mortality for RAASi and other antihypertensive agents using data from the international Dialysis Outcomes and Practice Patterns Study (DOPPS). Cox regression was used to estimate the effect of the prescription of RAASi and other antihypertensive agents at study entry on mortality in 11,421 incident (120 days or less) hemodialysis and 37,124 prevalent (over 120 days) hemodialysis patients from DOPPS phases 2-5 (2002-2015). Over 95% of RAASi were angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. RAASi prevalence was 39% and varied minimally by CHF and CAD. The adjusted hazard ratio for RAASi (vs. no RAASi) was 0.89 (95% confidence interval 0.80-0.99) among incident and 0.94 (0.90-0.99) among prevalent hemodialysis patients, with no convincing evidence of interaction with diabetes, CAD or CHF. Inverse associations with mortality were also observed for beta blockers and calcium channel blockers, and were stronger for angiotensin receptor blockers than angiotensin-converting enzyme inhibitors, but this latter finding requires further study. Thus, our observations suggest a relatively small survival benefit of RAASi and other antihypertensive agents in hemodialysis patients, though randomized prospective studies are needed to potentially change prescribing criteria.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Karaboyas A, Xu H, Morgenstern H, et al. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients. Kidney Int. 2018. PMID: 29908836. doi:10.1016/j.kint.2018.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。